Tuesday 13 October 2026
Export ARVN’s income statement to Excel — free account
Arvinas, Inc.
ARVN Healthcare Biotechnology
Arvinas, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $262.6 million, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 1,014.7%, EPS grew 410.7%, free cash flow grew 49.8% and total debt fell 40.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
7.01
0.44
−5.91%
Follow ARVN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(10.17%) | (16.23%) | (42.28%) | 1.59% | |
Piotroski F-Score |
4 | 4 | 3 | 6 | |
| (5.82%) | (8.93%) | (26.85%) | 1.17% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(8.52%) | (14.34%) | (42.53%) | 1.62% | |
Average Days of Receivables |
31.32 | 8.90 | 26.13 | 62.58 | |
Free Cash Flow per Share |
(4.50) | (3.89) | (4.01) | (3.22) | |
Free Cash Flow |
(329.50) | (275.70) | (256.90) | (208.80) | |
Capital Expenditures |
(2.00) | (1.90) | (2.80) | (1.80) | |
| Other line items | |||||
Cash ROIC |
(24.36%) | (24.62%) | (25.64%) | (18.47%) | |
Accounts Receivable Turnover |
15.01 | 26.13 | 12.08 | 9.69 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.27 | |
Inventory Turnover |
— | — | — | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 1,360.93 | |
Days of Inventory on Hand |
— | — | — | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | (0.07) | |
Research and Development Expense of Revenue |
98.43% | 108.61% | 284.90% | 75.37% | |
Selling, General and Administrative Expense of Revenue |
34.23% | 36.52% | 98.88% | 27.50% | |
Share Based Compensation of Revenue |
18.83% | 16.76% | 45.97% | 11.59% | |
Operating CF/Net income |
5.60 | 3.39 | 1.15 | (22.26) | |
Depreciation/Fixed assets |
(0.81) | (0.63) | (0.80) | 0.04 | |
Capex/Depreciation |
0.45 | 0.58 | 0.64 | (9.00) | |
Revenue per Share |
4.27 | 3.70 | 1.40 | 4.89 | |
Operating CF per Share |
(4.47) | (3.86) | (3.97) | (3.19) | |
Capex per Share |
(0.03) | (0.03) | (0.04) | (0.03) | |
Capex to Sales |
0.01 | 0.01 | 0.03 | 0.01 |
Columns are period end dates